Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample
Substance Use & Addiction Journal · 2024-04 · 45 (2) · 211-221
DOI: 10.1177/29767342231215178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Substance Use & Addiction Journal, online erschienen am 04.01.2024. Verfasst von Alysson E Light und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Pharmaceutical Services. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: NIDA NIH HHS, NIGMS NIH HHS, Substance Abuse and Mental Health Services Administration.
Abstract (Originalsprache)
Background
Concerns have been raised that pharmacists sometimes act as barriers to patients with opioid use disorder (OUD) accessing buprenorphine treatment. The present research explores how community pharmacists’ endorsement (vs non-endorsement) of stigmatizing beliefs about patients taking buprenorphine relate to intentions, comfort, and decisions regarding dispensing buprenorphine for OUD. In addition, we assessed attitudes toward risk in pharmacy practice as a novel correlate of dispensing intentions and decisions.
Methods
A sample of 207 active community-based pharmacists practicing in the United States responded to survey items measuring stigma, risk tolerance, and intentions to dispense buprenorphine. The survey included 2 vignettes in which patients presented to the pharmacy with a prescription for buprenorphine, and respondents rated their comfort with dispensing and decisions regarding dispensing in the vignette.
Results
Results suggest that both stigma toward patients taking buprenorphine to treat OUD and tolerance for risk in pharmacy settings are related to differences in pharmacists’ intentions to and willingness to dispense buprenorphine for OUD.
Conclusions
Findings support the need for interventions to reduce stigma associated with buprenorphine use among pharmacists and suggest that risk tolerance is an important determinant of pharmacists’ behavior that merits further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Chicago, Chicago, IL, USA.
- Brandeis University, Waltham, MA, USA.
- University of Kentucky, Lexington, KY, USA.
- American Pharmacists Association, Washington, DC, USA.
- The University of Texas at Austin, Austin, TX, USA.
ORCID-Profile: Alysson E Light
Förderung
- NIDA NIH HHS
- NIGMS NIH HHS
- Substance Abuse and Mental Health Services Administration
- National Institutes of Health
Zitieren
APA
Light, A. E., Green, T. C., Freeman, P. R., Zadeh, P. S., Burns, A. L., & Hill, L. G. (2024). Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample. Substance Use & Addiction Journal, 45(2), 211-221. https://doi.org/10.1177/29767342231215178
Vancouver
Light AE, Green TC, Freeman PR, Zadeh PS, Burns AL, Hill LG. Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample. Substance Use & Addiction Journal. 2024;45(2):211-221. doi:10.1177/29767342231215178
BibTeX
@article{Light2024,
author = {Light, Alysson E and Green, Traci C and Freeman, Patricia R and Zadeh, Paria Sanaty and Burns, Anne L and Hill, Lucas G},
title = {Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample},
journal = {Substance Use & Addiction Journal},
year = {2024},
volume = {45},
number = {2},
pages = {211--221},
doi = {10.1177/29767342231215178}
}
EUVIMED